Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 20/20 | 0.81 |
| ▸ | CLK3 | P49761 | 20/20 | 0.81 |
| ▸ | DYRK1A | Q13627 | 20/20 | 0.81 |
| ▸ | CLK1 | P49759 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 1/20 | 0.68 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.68 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.68 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15306694 | 0.93 | CLK2 (0.84) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL1270520 | 0.93 | CLK2 (0.84) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL12010077 | 0.93 | CLK2 (0.84) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15306593 | 0.92 | CLK2 (0.85) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL32557495 | 0.91 | CLK2 (0.87) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15301340 | 0.91 | CLK2 (0.87) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL23845839 | 0.91 | CLK2 (0.71) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15306887 | 0.90 | CLK2 (0.81) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15301389 | 0.90 | CLK2 (1.00) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL32557529 | 0.90 | CLK2 (1.00) | CLK2CLK3DYRK1ACLK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11667632-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667632-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-3915988-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BioSplice Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210292319-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-C]PYRIDINES AND THEIR ANTI-INFLAMMATORY USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2021-09-23 | — | — | US | disclosed |
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200190082-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10407425-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-09-10 | — | — | US | disclosed |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-10-10 | — | — | US | disclosed |
| WO-2013151708-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130040976-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040976-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-02-14 | — | — | US | disclosed |
| US-8252812-B2 | Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252812-B2 | Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2011019651-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20110034497-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034497-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | CLK2 574/4885CLK3 334/4885DYRK1A 423/4885 |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | CLK2 574/4885CLK3 334/4885DYRK1A 423/4885 |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 574/4885CLK3 334/4885DYRK1A 423/4885 |
| US-20110034497-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 510/4885CLK3 402/4885DYRK1A 436/4885 |
| US-20200190082-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 574/4885CLK3 334/4885DYRK1A 423/4885 |
| US-10407425-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | CLK2 574/4885CLK3 334/4885DYRK1A 423/4885 |
| US-20130040976-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 510/4885CLK3 402/4885DYRK1A 436/4885 |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 574/4885CLK3 334/4885DYRK1A 423/4885 |
| US-11667632-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof | IL33, IL4, IL1B | CLK2 2101/4885CLK3 1876/4885DYRK1A 3081/4885 |
| US-20210292319-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-C]PYRIDINES AND THEIR ANTI-INFLAMMATORY USES THEREOF | IL33, IL4, IL1B | CLK2 2101/4885CLK3 1876/4885DYRK1A 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.